You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR IPRATROPIUM BROMIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for IPRATROPIUM BROMIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00480194 ↗ Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM) Completed Nycomed 2006-12-01 The objectives of the study are to obtain knowledge about the safety in use, the patients' general impression of the treatment and the pattern of use of ZyComb® in an over-the-counter (OTC) setting.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for IPRATROPIUM BROMIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000568 ↗ Lung Health Study (LHS) I and III Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1984-09-01 In the Lung Health Study I, to determine the effects of Special Care, compared to Usual Care, on rate of decline in pulmonary function in a group of cigarette smokers identified as having mild abnormalities in pulmonary function. In the Lung Health Study III, to determine the long-term effects of smoking cessation and continued smoking, on cardiopulmonary morbidity, mortality, and the rate of decline in the one second forced expiratory volume (FEV1) in men and women with early chronic obstructive lung disease who have been followed prospectively for 12 to 15 years.
NCT00000577 ↗ Asthma Clinical Research Network (ACRN) Withdrawn National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1993-09-01 This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00000577 ↗ Asthma Clinical Research Network (ACRN) Withdrawn Milton S. Hershey Medical Center Phase 3 1993-09-01 This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00200967 ↗ Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) Completed Asthma Clinical Research Network Phase 3 2004-12-01 The purpose of this trial is to determine whether regularly scheduled use of an inhaled long-acting beta agonist (salmeterol) in the setting of concomitant use of inhaled corticosteroids (beclomethasone hydroflouroalkane (HFA) inhaler) will have a detrimental effect on asthma control in people who bear the B16-Arg/Arg genotype of the beta-2 adrenergic receptor gene, as compared to people with asthma of similar severity who bear the B16-Gly/Gly genotype.
NCT00200967 ↗ Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 2004-12-01 The purpose of this trial is to determine whether regularly scheduled use of an inhaled long-acting beta agonist (salmeterol) in the setting of concomitant use of inhaled corticosteroids (beclomethasone hydroflouroalkane (HFA) inhaler) will have a detrimental effect on asthma control in people who bear the B16-Arg/Arg genotype of the beta-2 adrenergic receptor gene, as compared to people with asthma of similar severity who bear the B16-Gly/Gly genotype.
NCT00200967 ↗ Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) Completed Milton S. Hershey Medical Center Phase 3 2004-12-01 The purpose of this trial is to determine whether regularly scheduled use of an inhaled long-acting beta agonist (salmeterol) in the setting of concomitant use of inhaled corticosteroids (beclomethasone hydroflouroalkane (HFA) inhaler) will have a detrimental effect on asthma control in people who bear the B16-Arg/Arg genotype of the beta-2 adrenergic receptor gene, as compared to people with asthma of similar severity who bear the B16-Gly/Gly genotype.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for IPRATROPIUM BROMIDE

Condition Name

Condition Name for IPRATROPIUM BROMIDE
Intervention Trials
Asthma 24
Pulmonary Disease, Chronic Obstructive 16
Chronic Obstructive Pulmonary Disease 11
COPD 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for IPRATROPIUM BROMIDE
Intervention Trials
Pulmonary Disease, Chronic Obstructive 37
Lung Diseases 33
Lung Diseases, Obstructive 27
Asthma 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for IPRATROPIUM BROMIDE

Trials by Country

Trials by Country for IPRATROPIUM BROMIDE
Location Trials
United States 114
Canada 11
Germany 7
United Kingdom 6
China 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for IPRATROPIUM BROMIDE
Location Trials
California 8
North Carolina 7
New York 7
Missouri 6
Colorado 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for IPRATROPIUM BROMIDE

Clinical Trial Phase

Clinical Trial Phase for IPRATROPIUM BROMIDE
Clinical Trial Phase Trials
Phase 4 28
Phase 3 23
Phase 2/Phase 3 1
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for IPRATROPIUM BROMIDE
Clinical Trial Phase Trials
Completed 60
Terminated 6
Unknown status 6
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for IPRATROPIUM BROMIDE

Sponsor Name

Sponsor Name for IPRATROPIUM BROMIDE
Sponsor Trials
Boehringer Ingelheim 23
GlaxoSmithKline 5
National Heart, Lung, and Blood Institute (NHLBI) 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for IPRATROPIUM BROMIDE
Sponsor Trials
Other 77
Industry 45
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.